These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 17418074)

  • 1. Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test.
    Nowakowski GS; Hoyer JD; Shanafelt TD; Geyer SM; LaPlant BR; Call TG; Jelinek DF; Zent CS; Kay NE
    Mayo Clin Proc; 2007 Apr; 82(4):449-53. PubMed ID: 17418074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Percentage of smudge cells determined on routine blood smears is a novel prognostic factor in chronic lymphocytic leukemia.
    Johansson P; Eisele L; Klein-Hitpass L; Sellmann L; Dührsen U; Dürig J; Nückel H
    Leuk Res; 2010 Jul; 34(7):892-8. PubMed ID: 20353875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive significance of smudge cell percentage on routine blood smear in chronic lymphocytic leukemia.
    Gogia A; Raina V; Gupta R; Gajendra S; Kumar L; Sharma A; Kumar R; Vishnubhatla S
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):514-7. PubMed ID: 24656596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia.
    Nowakowski GS; Hoyer JD; Shanafelt TD; Zent CS; Call TG; Bone ND; Laplant B; Dewald GW; Tschumper RC; Jelinek DF; Witzig TE; Kay NE
    J Clin Oncol; 2009 Apr; 27(11):1844-9. PubMed ID: 19255329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The prognostic value of smudge cells (Gumprecht shadows) in chronic lymphocytic leukaemia].
    Szerafin L; Jakó J; Riskó F; Hevessy Z
    Orv Hetil; 2012 Nov; 153(44):1732-7. PubMed ID: 23103742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status.
    Lech-Maranda E; Grzybowska-Izydorczyk O; Wyka K; Mlynarski W; Borowiec M; Antosik K; Cebula-Obrzut B; Makuch-Lasica H; Nowak G; Klimkiewicz-Wojciechowska G; Wawrzyniak E; Bilinski P; Robak T; Warzocha K
    Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):477-86. PubMed ID: 22945689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients.
    Meuleman N; Stamatopoulos B; Dejeneffe M; El Housni H; Lagneaux L; Bron D
    Leukemia; 2008 Oct; 22(10):1882-90. PubMed ID: 18633433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
    Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
    Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVH gene mutational status and other prognostic markers.
    Schwarz J; Mikulenková D; Cermáková M; Polanská V; Michalová K; Marinov I; Campr V; Ransdorfová S; Marková J; Pavlistová L; Brezinová J; Sajdová J; Sponerová D; Volková Z; Benesová K; Cermák J; Vítek A; Cetkovský P
    Neoplasma; 2006; 53(3):219-25. PubMed ID: 16652191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia.
    Molica S; Digiesi G; Battaglia C; Cutrona G; Antenucci A; Molica M; Giannarelli D; Sperduti I; Gentile M; Morabito F; Ferrarini M
    Eur J Haematol; 2010 Oct; 85(4):314-20. PubMed ID: 20546021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
    Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B
    Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters.
    Haferlach C; Dicker F; Weiss T; Schnittger S; Beck C; Grote-Metke A; Oruzio D; Kern W; Haferlach T
    Genes Chromosomes Cancer; 2010 Sep; 49(9):851-9. PubMed ID: 20552631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein lipase is differentially expressed in prognostic subsets of chronic lymphocytic leukemia but displays invariably low catalytical activity.
    Mansouri M; Sevov M; Fahlgren E; Tobin G; Jondal M; Osorio L; Roos G; Olivecrona G; Rosenquist R
    Leuk Res; 2010 Mar; 34(3):301-6. PubMed ID: 19709746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor.
    Zanotti R; Ambrosetti A; Lestani M; Ghia P; Pattaro C; Remo A; Zanetti F; Stella S; Perbellini O; Prato G; Guida G; Caligaris-Cappio F; Menestrina F; Pizzolo G; Chilosi M
    Leukemia; 2007 Jan; 21(1):102-9. PubMed ID: 17082778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic features and survival in young adults with early/intermediate chronic lymphocytic leukemia (B-CLL): a single institution study.
    Dhodapkar M; Tefferi A; Su J; Phyliky RL
    Leukemia; 1993 Aug; 7(8):1232-5. PubMed ID: 8350623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.
    Crespo M; Bosch F; Villamor N; Bellosillo B; Colomer D; Rozman M; Marcé S; López-Guillermo A; Campo E; Montserrat E
    N Engl J Med; 2003 May; 348(18):1764-75. PubMed ID: 12724482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High intracellular content of cyclin-dependent kinase inhibitor p27(Kip1) in early- and intermediate stage B-cell chronic lymphocytic leukemia lymphocytes predicts rapid progression of the disease.
    Wolowiec D; Wojtowicz M; Ciszak L; Kosmaczewska A; Frydecka I; Potoczek S; Urbaniak-Kujda D; Kapelko-Slowik K; Kuliczkowski K
    Eur J Haematol; 2009 Apr; 82(4):260-6. PubMed ID: 19187271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma.
    Ghobrial IM; Bone ND; Stenson MJ; Novak A; Hedin KE; Kay NE; Ansell SM
    Mayo Clin Proc; 2004 Mar; 79(3):318-25. PubMed ID: 15008605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum carbohydrate antigen 125 is not an independent prognostic factor in patients with chronic lymphocytic leukemia.
    Zou ZJ; Fan L; Wang L; Zhang R; Zhang LN; Yang S; Li JY; Xu W
    Cancer Biomark; 2012; 12(4):169-76. PubMed ID: 23568007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic lymphocytic leukemia and prognostic factors.
    Mozaheb Z; Hasanzadeh NazarAbadi MH; Aghaee MA
    Asian Pac J Cancer Prev; 2012; 13(7):3009-13. PubMed ID: 22994703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.